Table 3.
Biologics/tofacitinib index prescriptions, filling/administration status, and discrepancies between index prescription and first filling/administration post index
| Index prescription drug | Total number of patients (a + b) | Number of patients with no B/T filled/administered within 3 months, n (%) (a) | Number of patients with ≥1 B/T filled/administered within 3 months, n (%) (b) | First B/T filled/administered after index that was different from the index prescription (among b) | ||
|---|---|---|---|---|---|---|
| Anti-TNF biologics | ||||||
| Adalimumab (SC) | 118 | 56 | (47.5) | 62 | (52.5) | 10 etanercept |
| Certolizumab (SC) | 11 | 6 | (54.5) | 5 | (45.5) | 1 certolizumab IV |
| Etanercept (SC) | 202 | 65 | (32.2) | 137 | (67.8) | 1 adalimumab |
| Golimumab (SC) | 17 | 8 | (47.1) | 9 | (52.9) | None |
| Golimumab (IV) | 1 | – | 1 | (100.0) | None | |
| Infliximab (IV) | 28 | 14 | (50.0) | 14 | (50.0) | None |
| Non-anti-TNF biologics | ||||||
| Abatacept (IV) | 23 | 8 | (34.8) | 15 | (65.2) | 5 abatacept SC |
| Abatacept (SC) | 9 | 5 | (55.6) | 4 | (44.4) | None |
| Anakinra (SC) | 1 | – | 1 | (100.0) | None | |
| Rituximab (IV) | 7 | 4 | (57.1) | 3 | (42.9) | 1 abatacept SC |
| Tocilizumab (IV) | 2 | 1 | (50.0) | 1 | (50.0) | None |
| Tocilizumab (SC) | 1 | 1 | (100.0) | – | – | |
| New synthetic DMARD | ||||||
| Tofacitinib (oral) | 14 | 8 | (57.1) | 6 | (42.9) | None |
| Total | 434 | 176 | (40.6) | 258 | (59.4) | 18 discrepancies |
B/T biologics/tofacitinib, TNF tumor necrosis factor, SC subcutaneous, IV intravenous infusion, DMARD disease-modifying anti-rheumatic drug